Microscopical Variables and Tumor Inflammatory Microenvironment Do Not Modify Survival or Recurrence in Stage I-IIA Lung Adenocarcinomas.
PD-L1
TILs
adenocarcinomas
early-stage lung adenocarcinoma
lung cancer
pathological score
pathological variables
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Sep 2023
13 Sep 2023
Historique:
received:
04
08
2023
revised:
08
09
2023
accepted:
12
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Microscopical predictors and Tumor Immune Microenvironment (TIME) have been studied less in early-stage NSCLC due to the curative intent of resection and the satisfactory survival rate achievable. Despite this, the emerging literature enforces the role of the immune system and microscopical predictors as prognostic variables in NSCLC and in adenocarcinomas (ADCs) as well. Here, we investigated whether cancer-related microscopical variables and TIME influence survival and recurrence in I-IIA ADCs. We retrospectively collected I-IIA ADCs treated (lobectomy or segmentectomy) at the University Hospital (Padova) between 2016 and 2022. We assigned to pathological variables a cumulative pathological score (PS) resulting as the sum of them. TIME was investigated as tumor-infiltrating lymphocytes (TILs < 11% or ≥11%) and PD-L1 considering its expression (<1% or ≥1%). Then, we compared survival and recurrence according to PS, histology, TILs and PD-L1. A total of 358 I-IIA ADCs met the inclusion criteria. The median PS grew from IA1 to IIA, indicating an increasing microscopical cancer activity. Except for the T-SUVmax, any pathological predictor seemed to be different between PD-L1 < 1% and ≥1%. Histology, PS, TILs and PD-L1 were unable to indicate a survival difference according to the Log-rank test (
Identifiants
pubmed: 37760512
pii: cancers15184542
doi: 10.3390/cancers15184542
pmc: PMC10527442
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncogene. 2019 Aug;38(31):5921-5932
pubmed: 31253869
Pathologica. 2018 Mar;110(1):5-11
pubmed: 30259909
Lancet. 2021 Oct 9;398(10308):1344-1357
pubmed: 34555333
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
NPJ Precis Oncol. 2022 Jan 13;6(1):2
pubmed: 35027673
PLoS One. 2015 Aug 27;10(8):e0136023
pubmed: 26313362
N Engl J Med. 2022 May 26;386(21):1973-1985
pubmed: 35403841
Cell Mol Immunol. 2021 Apr;18(4):842-859
pubmed: 33139907
Mod Pathol. 2022 Dec;35(12):1848-1859
pubmed: 35915139
Cancers (Basel). 2022 Mar 09;14(6):
pubmed: 35326552
Br J Cancer. 2023 Feb;128(3):451-458
pubmed: 36564565
Cancers (Basel). 2021 Apr 17;13(8):
pubmed: 33920510
Front Oncol. 2020 Sep 25;10:564915
pubmed: 33072595
Lung Cancer. 2015 Aug;89(2):181-8
pubmed: 26024796
Lancet Oncol. 2016 Dec;17(12):e542-e551
pubmed: 27924752
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
N Engl J Med. 2018 May 24;378(21):1976-1986
pubmed: 29658848
Nat Commun. 2021 Jun 25;12(1):3969
pubmed: 34172722
Lancet Oncol. 2022 Oct;23(10):1274-1286
pubmed: 36108662
Br J Cancer. 2019 Mar;120(5):547-554
pubmed: 30745585
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Front Immunol. 2023 Jan 05;13:1038089
pubmed: 36660547
Cancer Immunol Immunother. 2021 Apr;70(4):1063-1074
pubmed: 33113005
EClinicalMedicine. 2021 Sep 16;41:101134
pubmed: 34585125
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
J Thorac Oncol. 2017 May;12(5):791-803
pubmed: 28088513
J Immunother Cancer. 2022 Jun;10(6):
pubmed: 35649657
NPJ Precis Oncol. 2022 Jun 3;6(1):33
pubmed: 35661148
Sci Rep. 2017 Oct 19;7(1):13543
pubmed: 29051570